BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 35114411)

  • 1. Prospective Phase II Trial of Montelukast to Treat Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation and Investigation into Bronchiolitis Obliterans Syndrome Pathogenesis.
    Williams KM; Pavletic SZ; Lee SJ; Martin PJ; Farthing DE; Hakim FT; Rose J; Manning-Geist BL; Gea-Banacloche JC; Comis LE; Cowen EW; Justus DG; Baird K; Cheng GS; Avila D; Steinberg SM; Mitchell SA; Gress RE
    Transplant Cell Ther; 2022 May; 28(5):264.e1-264.e9. PubMed ID: 35114411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review of the therapeutic potential of the cysteinyl leukotriene antagonist Montelukast in the treatment of bronchiolitis obliterans syndrome following lung and hematopoietic-stem cell transplantation and its possible mechanisms.
    Kordjazy N; Amini S
    Ther Adv Respir Dis; 2024; 18():17534666241232284. PubMed ID: 38504551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluticasone, Azithromycin, and Montelukast Treatment for New-Onset Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation.
    Williams KM; Cheng GS; Pusic I; Jagasia M; Burns L; Ho VT; Pidala J; Palmer J; Johnston L; Mayer S; Chien JW; Jacobsohn DA; Pavletic SZ; Martin PJ; Storer BE; Inamoto Y; Chai X; Flowers MED; Lee SJ
    Biol Blood Marrow Transplant; 2016 Apr; 22(4):710-716. PubMed ID: 26475726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lung Function Trajectory in Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Cell Transplant.
    Cheng GS; Storer B; Chien JW; Jagasia M; Hubbard JJ; Burns L; Ho VT; Pidala J; Palmer J; Johnston L; Mayer S; Crothers K; Pusic I; Lee SJ; Williams KM
    Ann Am Thorac Soc; 2016 Nov; 13(11):1932-1939. PubMed ID: 27513368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic effect of budesonide/formoterol, montelukast and N-acetylcysteine for bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation.
    Kim SW; Rhee CK; Kim YJ; Lee S; Kim HJ; Lee JW
    Respir Res; 2016 May; 17(1):63. PubMed ID: 27229850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Montelukast for bronchiolitis obliterans syndrome after lung transplantation: A randomized controlled trial.
    Ruttens D; Verleden SE; Demeyer H; Van Raemdonck DE; Yserbyt J; Dupont LJ; Vanaudenaerde BM; Vos R; Verleden GM
    PLoS One; 2018; 13(4):e0193564. PubMed ID: 29624575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk Factors for Bronchiolitis Obliterans Syndrome after Initial Detection of Pulmonary Impairment after Hematopoietic Cell Transplantation.
    Alkhunaizi M; Patel B; Bueno L; Bhan N; Ahmed T; Arain MH; Saliba R; Rondon G; Dickey BF; Bashoura L; Ost DE; Li L; Wang S; Shpall E; Champlin RE; Mehta R; Popat UR; Hosing C; Alousi AM; Sheshadri A
    Transplant Cell Ther; 2023 Mar; 29(3):204.e1-204.e7. PubMed ID: 36503180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidemiology of Lower Respiratory Tract Infections and Community-Acquired Respiratory Viruses in Patients with Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation: A Retrospective Cohort Study.
    Epstein DJ; Liang EC; Sharifi H; Lai YK; Arai S; Graber-Naidich A; Sundaram V; Nelson J; Hsu JL
    Transplant Cell Ther; 2022 Oct; 28(10):705.e1-705.e10. PubMed ID: 35872303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Montelukast for bronchiolitis obliterans syndrome after lung transplantation: a pilot study.
    Verleden GM; Verleden SE; Vos R; De Vleeschauwer SI; Dupont LJ; Van Raemdonck DE; Vanaudenaerde BM
    Transpl Int; 2011 Jul; 24(7):651-6. PubMed ID: 21401732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early Post-Transplantation Spirometry Is Associated with the Development of Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Cell Transplantation.
    Jamani K; He Q; Liu Y; Davis C; Hubbard J; Schoch G; Lee SJ; Gooley T; Flowers MED; Cheng GS
    Biol Blood Marrow Transplant; 2020 May; 26(5):943-948. PubMed ID: 31821885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The safety and tolerability of pirfenidone for bronchiolitis obliterans syndrome after hematopoietic cell transplant (STOP-BOS) trial.
    Matthaiou EI; Sharifi H; O'Donnell C; Chiu W; Owyang C; Chatterjee P; Turk I; Johnston L; Brondstetter T; Morris K; Cheng GS; Hsu JL
    Bone Marrow Transplant; 2022 Aug; 57(8):1319-1326. PubMed ID: 35641662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relevance of Plasma Matrix Metalloproteinase-9 for Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Cell Transplantation.
    Inamoto Y; Martin PJ; Onstad LE; Cheng GS; Williams KM; Pusic I; Ho VT; Arora M; Pidala J; Flowers MED; Gooley TA; Lawler RL; Hansen JA; Lee SJ
    Transplant Cell Ther; 2021 Sep; 27(9):759.e1-759.e8. PubMed ID: 34126278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inert Gas Washout in Bronchiolitis Obliterans Following Hematopoietic Cell Transplantation.
    Nyilas S; Baumeler L; Tamm M; Halter JP; Savic S; Korten I; Meyer A; Singer F; Passweg JR; Latzin P; Stolz D
    Chest; 2018 Jul; 154(1):157-168. PubMed ID: 29275133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of safety and efficacy of allogeneic adipose tissue-derived mesenchymal stem cells in pediatric bronchiolitis obliterans syndrome (BoS) after allogeneic hematopoietic stem cell transplantation (allo-HSCT).
    Mohseni R; Mahdavi Sharif P; Behfar M; Modaresi MR; Shirzadi R; Mardani M; Jafari L; Jafari F; Nikfetrat Z; Hamidieh AA
    Stem Cell Res Ther; 2023 Sep; 14(1):256. PubMed ID: 37726865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicenter evaluation of parametric response mapping as an indicator of bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation.
    Cheng GS; Selwa KE; Hatt C; Ram S; Fortuna AB; Guerriero M; Himelhoch B; McAree D; Hoffman TC; Brisson J; Nazareno R; Bloye K; Johnson TD; Remberger M; Mattsson J; Vummidi D; Kazerooni EE; Lama VN; Galban S; Boeckh M; Yanik GA; Galban CJ
    Am J Transplant; 2020 Aug; 20(8):2198-2205. PubMed ID: 32034974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic role of FEV1 for survival in bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation.
    Ahn JH; Jo KW; Song JW; Shim TS; Lee SW; Lee JS; Kim DY; Lee JH; Lee JH; Choi Y; Lee KH
    Clin Transplant; 2015 Dec; 29(12):1133-9. PubMed ID: 26383085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LTB4 and montelukast in transplantation-related bronchiolitis obliterans in rats.
    Tu ZL; Zhou ZY; Xu HC; Cao JL; Ye P; Wang LM; Lv W; Hu J
    J Cardiothorac Surg; 2017 May; 12(1):43. PubMed ID: 28545478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid versus gradual lung function decline in bronchiolitis obliterans syndrome after haematopoietic stem cell transplantation is associated with survival outcome.
    Kwok WC; Liang BM; Lui MMS; Tam TCC; Sim JPY; Tse EWC; Leung AYH; Kwong YL; Lie AKW; Ip MSM; Lam DCL
    Respirology; 2019 May; 24(5):459-466. PubMed ID: 30663178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Rituximab on Pulmonary Function in Bronchiolitis Obliterans Syndrome due to Graft-Versus-Host-Disease.
    Brownback KR; Thomas LA; McGuirk JP; Ganguly S; Streiler C; Abhyankar S
    Lung; 2017 Dec; 195(6):781-788. PubMed ID: 28894914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation-an increasingly recognized manifestation of chronic graft-versus-host disease.
    Chien JW; Duncan S; Williams KM; Pavletic SZ
    Biol Blood Marrow Transplant; 2010 Jan; 16(1 Suppl):S106-14. PubMed ID: 19896545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.